Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ABVC BioPharma, Inc. (ABVC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
0.5203-0.0747 (-12.55%)
At close: 04:00PM EDT
0.5510 +0.03 (+5.90%)
After hours: 07:45PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Performance Outlook
Previous Close0.5950
Open0.5960
Bid0.5500 x 1000
Ask0.5300 x 1000
Day's Range0.5000 - 0.6401
52 Week Range0.5000 - 11.6900
Volume291,546
Avg. Volume112,841
Market Cap16.809M
Beta (5Y Monthly)0.52
PE Ratio (TTM)N/A
EPS (TTM)-0.6710
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ABVC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ABVC Biopharma, Inc.
    Analyst Report: Sherwin-Williams Co.Sherwin-Williams is the largest U.S. producer of paint, coatings and related products. The company operates over 4,100 retail stores and supplies coatings directly to retailers, distributors, industrial & commercial customers, and other industry professionals. The company acquired Valspar in 2017.
    Rating
    Fair Value
    Economic Moat
    10 days agoArgus Research
View more
  • GlobeNewswire

    ABVC BioPharma Provides Vitargus® Update

    Phase II Vitargus® Clinical Study Protocol Receives Local Ethics Committee Approval FREMONT, CA, Aug. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Ethics Committee (“EC”) of Srinagarind Hospital, Khon Kaen University of Thailand approved the Vitargus Phase II Clinical Study Protocol (ABV-1701-02). Srinagarind

  • GlobeNewswire

    ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028

    -- Growth to benefit ABVC’s Vitargus medical device product -- FREMONT, CA, July 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that, according to a recent study by Bosson Research, the global Retinal Surgical Instruments market, valued at USD 1.59 billion in 2021, is expected to reach USD2.46 billion by the end of 2028,

  • GlobeNewswire

    ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update

    FREMONT, CA, July 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the enrollment progress in the Phase II Part II clinical study of the Company’s ADHD medicine (ABV-1505). Since results on the first subject treated were reported on May 10, 2022, a total of 22 subjects have been enrolled in the study from a total of 32 sub

Advertisement
Advertisement